Autoimmune Disease Series--
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and fatal form of interstitial pneumonia characterized by irreversible fibrotic remodeling of lung tissue, ultimately leading to respiratory failure. Its core pathological mechanisms include repeated injury to alveolar epithelial cells and abnormal repair processes, which drive the activation of fibroblasts into myofibroblasts. This results in excessive deposition of extracellular matrix, forming pulmonary scars.
Clinically, it presents with exertional dyspnea, dry cough, and fatigue, often accompanied by progressive decline in lung function. Approximately 50% of patients also have interstitial lung disease (ILD). IPF primarily affects individuals over 50 years old, with a median survival of only 2-5 years. Its prognosis is worse than many cancers, earning it the moniker "the cancer that isn't cancer."
Drug development for Idiopathic Pulmonary Fibrosis (IPF) focuses on core mechanisms like fibrosis, inflammation, and cellular repair, targeting key pathways including:
● Transforming Growth Factor-beta (TGF-β) Pathway: The existing drug nintedanib delays lung function decline by inhibiting TGF-β downstream receptors (VEGFR, PDGFR, FGFR). Bristol Myers Squibb's BMS-986278 (Admilparant), a lysophosphatidic acid receptor 1 (LPAR1) antagonist, demonstrated a 54% reduction in the annual rate of forced vital capacity (FVC) decline in its Phase II study and is currently in Phase III trials.
● Phosphodiesterase 4B (PDE4B): Boehringer Ingelheim's oral inhibitor nerandomilast significantly slowed FVC decline in the Phase III FIBRONEER-IPF trial with a manageable safety profile. It has been submitted for marketing approval in China and granted priority review.
● Connective Tissue Growth Factor (CTGF): Pliant Therapeutics' bexotegrast (PLN-74809), which inhibits the binding of CTGF to TGF-β, showed reduced FVC decline in a Phase IIa study and is now advancing to Phase IIb/III trials.
Current IPF drug discovery is breaking new ground with multi-target approaches and novel mechanisms. Insilico Medicine leveraged AI to discover the TNIK kinase inhibitor INS018_055, which demonstrated superior anti-fibrotic effects to nintedanib in preclinical studies and synergistic effects when combined with pirfenidone. The National Institute of Biological Sciences, Beijing (NIBS), identified AREG protein as a key target, and its inhibitor has entered Phase I clinical trials. In the realm of cell therapies, Shanghai Jiao Tong University's autologous basal stem cell transplantation and Genmir Biotech's REGEND001 airway basal stem cell therapy have both shown positive outcomes, including improved lung function, in clinical trials. Furthermore, Korean research confirmed that ezetimibe inhibits fibroblast differentiation, and Chinese scientists identified the GOLM1-KLF4-NEAT1 signaling pathway as having potential value, offering new hope for IPF treatment.
Idiopathic Pulmonary Fibrosis Drug Targets in Development:
Idiopathic Pulmonary Fibrosis Drug Targets Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized Rhesus macaque CTGF at 1 μg/ml can bind Anti-CTGF recombinant antibody (CSB-RA006147MA2HU). The EC50 is 0.6886-0.7825 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m,antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL.
-AC1.jpg)
Measured by its binding ability in a functional ELISA. Immobilized Human CXCR4 at 10 μg/ml can bind Anti-CXCR4 recombinant antibody (CSB-RA006254MA01HU), the EC50 is 101.7-253.6 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized CD73 at 2 μg/ml can bind Anti- CD73 Rabbit Monoclonal Antibody(CSB-RA978310A0HU), the EC50 is 3.212-4.525 ng/ml.
| Target |
Product Name |
Source |
Tag Info |
Product Code |
| CCL2 |
Recombinant Human C-C motif chemokine 2 (CCL2) |
E.coli |
N-terminal GST-tagged |
CSB-EP004783HU |
| CCL2 |
Recombinant Human C-C motif chemokine 2 (CCL2) |
E.coli |
N-terminal 10xHis-tagged and C-terminal Myc-tagged |
CSB-EP004783HUb1 |
| CCL2 |
Recombinant Mouse C-C motif chemokine 2 (Ccl2), partial |
E.coli |
N-terminal 6xHis-tagged |
CSB-EP004783MO |
| CCN2 |
Recombinant Human CCN family member 2 (CCN2) |
E.coli |
C-terminal 6xHis-tagged |
CSB-EP006147HU |
| CCN2 |
Recombinant Human CCN family member 2 (CCN2), partial |
E.coli |
N-terminal 6xHis-tagged |
CSB-EP006147HU1 |
| Ccn2 |
Recombinant Mouse CCN family member 2 (Ccn2), partial |
E.coli |
N-terminal 10xHis-SUMO-tagged |
CSB-EP006147MO |
| Ccn2 |
Recombinant Mouse CCN family member 2 (Ccn2), partial |
E.coli |
N-terminal GST-tagged |
CSB-EP006147MOe0 |
| CCN2 |
Recombinant Macaca mulatta CCN family member 2 (CCN2) (Active) |
Mammalian cell |
C-terminal 10xHis-tagged |
CSB-MP5112MOW |
| Ccn4 |
Recombinant Rat CCN family member 4 (Ccn4), Biotinylated |
E.coli |
N-terminal MBP-tagged and C-terminal 6xHis-Avi-tagged |
CSB-EP857523RA-B |
| CCR7 |
Recombinant Human C-C chemokine receptor type 7 (CCR7), partial |
E.coli |
N-terminal 10xHis-tagged and C-terminal Myc-tagged |
CSB-EP004846HU1 |
| CCR7 |
Recombinant Human C-C chemokine receptor type 7 (CCR7) |
in vitro E.coli expression system |
N-terminal 6xHis-tagged |
CSB-CF004846HUa0 |
| CD274 |
Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial |
E.coli |
N-terminal 10xHis-tagged and C-terminal Myc-tagged |
CSB-EP878942HU2 |
| CD274 |
Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial (Active) |
Mammalian cell |
C-terminal hFc1-tagged |
CSB-MP878942HU1 |
| CD274 |
Recombinant Dog CD274 molecule (CD274), partial |
Mammalian cell |
C-terminal 10xHis-tagged |
CSB-MP5015DO1 |
| CD274 |
Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial ( (K136A)) |
E.coli |
N-terminal 6xHis-tagged |
CSB-EP878942HU1(M) |
| CD274 |
Recombinant Human Programmed cell death 1 ligand 1 (CD274) (K136A), partial |
Yeast |
C-terminal 6xHis-tagged |
CSB-YP878942HU1(M)c7 |
| CD274 |
Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial |
Mammalian cell |
C-terminal 10xHis-tagged |
CSB-MP878942HU1d7 |
| Cldn1 |
Recombinant Rat Claudin-1 (Cldn1), partial |
E.coli |
N-terminal 10xHis-tagged and C-terminal Myc-tagged |
CSB-EP005490RA1 |
| CLDN1 |
Recombinant Human Claudin-1 (CLDN1) |
in vitro E.coli expression system |
N-terminal 10xHis-tagged |
CSB-CF005490HU |
| CLDN1 |
Recombinant Human Claudin-1 (CLDN1)-VLPs |
Mammalian cell |
C-terminal 10xHis-tagged (This tag can be tested only under denaturing conditions) |
CSB-MP005490HU |
● Antibodies
Tested Applications:
ELISA, IHC, FC
Tested Applications:
ELISA, WB, IHC
Tested Applications:
ELISA, WB, IF
Tested Applications:
ELISA, WB, IHC
- Recombinant Antibody
| Target |
Product Name |
Species Reactivity |
Tested Applications |
Code |
| CD274 |
CD274 Recombinant Monoclonal Antibody |
Human |
ELISA, WB, IHC |
CSB-RA977797A0HU |
| CD274 |
CD274 Recombinant Monoclonal Antibody |
Human |
ELISA, IHC, FC |
CSB-RA878942MA1HU |
| CD38 |
CD38 Recombinant Monoclonal Antibody |
Human |
ELISA, WB, IHC |
CSB-RA796695A0HU |
| CD40 |
CD40 Recombinant Monoclonal Antibody |
Human |
ELISA, IF, FC |
CSB-RA004936MA1HU |
| GCGR |
GCGR Recombinant Monoclonal Antibody |
Human |
ELISA |
CSB-RA009316A1HU |
| IL17A |
IL17A Recombinant Monoclonal Antibody |
Human |
ELISA |
CSB-RA624104MA1HU |
| IL23A |
IL23A Recombinant Monoclonal Antibody |
Human |
ELISA, WB |
CSB-RA251959A0HU |
| IL6 |
IL6 Recombinant Monoclonal Antibody |
Human |
ELISA |
CSB-RA011664MA1HU |
| ITGAL |
ITGAL Recombinant Monoclonal Antibody |
Human |
ELISA, WB, IF |
CSB-RA787996A0HU |
| MS4A1 |
CD20 Recombinant Monoclonal Antibody |
Human |
ELISA |
CSB-RA015007A0HU |
| MS4A1 |
MS4A1 Recombinant Monoclonal Antibody |
Human |
ELISA |
CSB-RA015007A1HU |
| MS4A1 |
MS4A1 Recombinant Monoclonal Antibody |
Human, Dog, Macaca fascicularis |
ELISA |
CSB-RA015007MA3HU |
| MS4A1 |
MS4A1 Recombinant Monoclonal Antibody |
Human |
ELISA, IHC, IF |
CSB-RA015007MA4HU |
| PCSK9 |
PCSK9 Recombinant Monoclonal Antibody |
Human |
ELISA, WB, IHC |
CSB-RA259644A0HU |
| SELPLG |
SELPLG Recombinant Monoclonal Antibody |
Human |
ELISA, IHC |
CSB-RA567010A0HU |
- Monoclonal Antibody
| Target |
Product Name |
Species Reactivity |
Tested Applications |
Code |
| CD2 |
CD2 Monoclonal Antibody |
Human,Mouse,Rat |
ELISA, IHC |
CSB-MA000227 |
| CD2 |
CD2 Monoclonal Antibody,FITC Conjugated |
Human |
ELISA, IF, FC |
CSB-MA785710 |
| CD38 |
CD38 Monoclonal Antibody |
Human |
ELISA, IHC |
CSB-MA785760 |
| IL1B |
IL1B Monoclonal Antibody |
Human |
ELISA |
CSB-MA065741A0m |
| IL1B |
IL1B Monoclonal Antibody |
Human |
ELISA, WB, IHC, ICC |
CSB-MA010884 |
| IL6 |
IL6 Monoclonal Antibody |
Human |
ELISA, WB, IHC |
CSB-MA067571A0m |
| ITGAL |
ITGAL Monoclonal Antibody,FITC Conjugated |
Human |
ELISA, IF, FC |
CSB-MA120024 |
| ITGAL |
ITGAL Monoclonal Antibody,PE Conjugated |
Human |
ELISA, IF, FC |
CSB-MA897229 |
| MS4A1 |
MS4A1 Monoclonal Antibody |
Human,Mouse,Rat |
ELISA, IHC |
CSB-MA000204 |
| MS4A1 |
MS4A1 Monoclonal Antibody |
Human |
ELISA, IHC |
CSB-MA996413 |
| TNF |
TNF Monoclonal Antibody |
Bovine |
ELISA |
CSB-MA084771A0m |
| TNF |
TNF Monoclonal Antibody |
Human,Mouse,Rat |
ELISA, WB, IHC |
CSB-MA080271 |
| TNF |
TNF Monoclonal Antibody |
Human,Mouse,Rat |
ELISA, WB, IHC |
CSB-MA080272 |
- Polyclonal Antibody
| Target |
Product Name |
Species Reactivity |
Tested Applications |
Code |
| CD2 |
CD2 Antibody |
Human |
ELISA, IHC, IF |
CSB-PA004894LA01HU |
| CD2 |
CD2 Antibody |
Human |
ELISA, WB |
CSB-PA005194 |
| CD2 |
CD2 Antibody |
Human |
ELISA, WB |
CSB-PA004894GA01HU |
| CD274 |
CD274 Antibody |
Human |
ELISA, IHC |
CSB-PA878942ESR1HU |
| CD274 |
CD274 Antibody |
Human, Mouse, Rat |
ELISA, WB, IHC |
CSB-PA004911GA01HU |
| CD28 |
CD28 Antibody |
Human |
ELISA, WB |
CSB-PA005199 |
| CD28 |
Phospho-CD28 (Y218) Antibody |
Human, Mouse |
ELISA, WB |
CSB-PA070302 |
| CD38 |
CD38 Antibody |
Human |
ELISA, IHC |
CSB-PA004929ESR1HU |
| CD38 |
CD38 Antibody |
Human |
ELISA, WB |
CSB-PA005628 |
| CD38 |
CD38 Antibody |
Human |
ELISA, WB |
CSB-PA134528 |
| CD38 |
CD38 Antibody |
Human |
ELISA, WB, IHC |
CSB-PA926996 |
| CD3D |
CD3D Antibody |
Human |
ELISA, IHC |
CSB-PA004930ESR1HU |
| CD3D |
CD3D Antibody |
Human |
ELISA, WB |
CSB-PA001452 |
| CD3D |
CD3D Antibody |
Human |
ELISA, WB |
CSB-PA005826 |
| CD3D |
CD3D Antibody |
Human, Mouse, Rat |
ELISA, WB, IF |
CSB-PA004930GA01HU |
| CD40 |
CD40 Antibody |
Human, Mouse |
ELISA, WB, IF |
CSB-PA004936LA01HU |
| CD40 |
CD40 Antibody |
Human, Mouse, Monkey |
ELISA, WB, IHC |
CSB-PA001455 |
| CD40 |
Phospho-CD40 (T254) Antibody |
Human, Mouse |
ELISA, WB |
CSB-PA080031 |
| CD40 |
CD40 Antibody |
Human |
ELISA, WB |
CSB-PA004936GA01HU |
| CD40 |
CD40 Antibody |
Human, Mouse |
ELISA, IHC |
CSB-PA215588 |
● ELISA Kits
| Target |
Product Name |
Sample Types |
Detection Range |
Code |
| CCL2 |
Human high sensitivity C-C motif chemokine 2 (CCL2) ELISA kit |
serum, plasma, tissue homogenates |
6.25 pg/mL-400 pg/mL |
CSB-EQ004783HU |
| TGFB1 |
Rat Transforming Growth Factor β1(TGF-β1) ELISA kit |
serum, plasma, cell culture supernates, tissue homogenates |
6.25 pg/mL-400 pg/mL |
CSB-E04727r |
| TGFB1 |
Human Transforming Growth factor β1,TGF-β1 ELISA kit |
serum, plasma, cell culture supernates |
0.78 ng/mL-50 ng/mL |
CSB-E04725h |
| TGFB1 |
Mouse Transforming Growth factor β1,TGF-β1 ELISA kit |
serum, plasma, cell culture supernates |
0.78 ng/mL-50 ng/mL |
CSB-E04726m |
| CCL2 |
Mouse monocyte chemotactic protein 1/monocyte chemotactic and activating factor,MCP-1/MCAF ELISA kit |
serum, plasma, tissue homogenates |
78 pg/mL-5000 pg/mL |
CSB-E07430m |
| CCL2 |
Rat monocyte chemotactic protein 1/monocyte chemotactic and activating factor,MCP-1/MCAF ELISA kit |
serum, plasma, tissue homogenates |
31.25 pg/mL-2000 pg/mL |
CSB-E07429r |
| IL13 |
Mouse Interleukin 13,IL-13 ELISA Kit |
serum, plasma, tissue homogenates |
78 pg/ml - 5000 pg/ml |
CSB-E04602m |
| CCL2 |
Human monocyte chemotactic protein 1/monocyte chemotactic and activating factor,MCP-1/MCAF ELISA kit |
serum, plasma, urine, saliva, cerebrospinal fluid (CSF), ascitic fluid, cell culture supernates, tis |
6.25 pg/ml-400 pg/ml. |
CSB-E04655h |
| CD274 |
Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit |
serum, plasma, tissue homogenates, cell lysates |
15.6 pg/mL-1000 pg/mL |
CSB-E13644h |
| IL13 |
Rat Interleukin 13,IL-13 ELISA KIT |
serum, plasma, cell culture supernates, tissue homogenates |
7.8 pg/mL-500 pg/mL |
CSB-E07454r |
| TGFB1 |
Chicken Transforming Growth factor β1,TGF-β1 ELISA kit |
serum, plasma, tissue homogenates |
0.312 ng/mL-20 ng/mL |
CSB-E09875Ch |
| IL13 |
Human Interleukin 13,IL-13 ELISA KIT |
serum, plasma, tissue homogenates |
0.39 ng/ml-25 ng/ml. |
CSB-E04601h |
| CLDN1 |
Human Claudin-1(CLDN1) ELISA kit |
serum, plasma, tissue homogenates, cell lysates |
15.6 pg/mL-1000 pg/mL |
CSB-EL005490HU |
| TGFB1 |
Pig transforming growth factor β1(TGF-β1)ELISA Kit |
serum, plasma |
0.78 ng/mL-50 ng/mL |
CSB-E06843p |
| IL11 |
Mouse Interleukin 11,IL-11 ELISA KIT |
serum, plasma, tissue homogenates |
78 pg/ml - 5000 pg/ml |
CSB-E04597m |
| CCL2 |
Rabbit monocyte chemotactic protein 1/monocyte chemotactic and activating factor,MCP1/MCAF ELISA kit |
serum, plasma, tissue homogenates |
23.5 pg/mL-1500 pg/mL |
CSB-E06921Rb |
| ENO1 |
Human Alpha-enolase (ENO1/ENO1L1/MBPB1/MPB1) ELISA kit |
serum, tissue homogenates, plasma |
0.312 ng/mL-20 ng/mL |
CSB-E17177h |
| CXCR4 |
Rat CXC-chemokine receptor 4(CXCR4)ELISA Kit |
serum, plasma, cell culture supernates, tissue homogenates |
0.156 ng/mL-10 ng/mL |
CSB-E12703r |
| CXCR4 |
Human CXC-chemokine receptor 4(CXCR4)ELISA Kit |
serum, plasma, tissue homogenates |
15.6 pg/mL-1000 pg/mL |
CSB-E12825h |
| CCL2 |
Pig monocyte chemotactic protein 1,MCP1 ELISA Kit |
serum, plasma |
31.25 pg/mL-2000 pg/mL |
CSB-E13178p |
Drug Development Solutions
